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Abstract
Background: Incarceration has been associated with HIV infection among injection drug users.
However, data on HIV risk factors of the inmates during incarceration are rarely reported from
Thailand.
Methods: A prospective cohort of 689 male inmates in a Bangkok central prison was studied
during 2001–2002. Follow up visits were conducted for 5 months, with testing for HIV and other
infections and interviewing of demographics and risk behaviors.
Results: Among 689 male inmates, half (50.9 %) were drug injectors. About 49% of the injectors
had injection during incarceration. Most (94.9%) of the injectors had shared injection paraphernalia
with others. Successful follow up rate was 98.7% after 2,581 person-months observation. HIV
incidence was 4.18 per 100 person – years among all inmates, and 11.10 per 100 person – years
among the injection inmates. Multivariate analysis identified variables associated with HIV
prevalence: history of injection [OR = 2.30, 95%CI: 1.91–2.77], positive urine opiate test [OR =
5.04, 95%CI: 2.63–9.67], history of attendance to drug withdrawal clinics [OR = 2.00, 95%CI: 1.19–
3.35] and presence of tattoos on the body [OR = 1.23, 95%CI: 1.01–1.52].
Conclusions: The main HIV risk factors of Bangkok inmates were those related to drug injection.
Harm reduction measures and HIV intervention strategies should be implemented to prevent more
spread of HIV among the inmates and into the community.
Background
The problem of human immunodeficiency virus (HIV)
infection and acquired immunodeficiency syndrome
(AIDS) is usually approached from a perspective of risk
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behaviors and modes of transmission. In Thailand, this
approach has been implemented since 1989 for HIV sen-
tinel surveillance of certain high-risk people; e.g. commer-
cial sex workers, injection drug users and male clients
attending sexually transmitted diseases clinics [1]. As far
as interventions are concerned, such an approach leaves
certain target groups not presenting at the usual settings
unaccounted for. For instance, men who have sex with
men do not have "well-defined" physical places where
they usually meet and are less likely to receive targeted
HIV-1 related interventions. On the other hand, certain
HIV high-risk groups in well-defined but restricted set-
tings are also left out from interventions they deserve.
Inmates are an example of the left-out population. HIV-1
seroprevalence of the inmates in the United States, Brazil
and Scotland have been reported at 20.3, 13.7 and 5.8%,
respectively [2–4]. No such data of Thai inmates have
been reported so far, however. The lack of information
from inmates may be due to several reasons. First, inmates
are sensitive people to study and most investigators find it
difficult to gain public acceptance and access to this
group. Second, inmates are marginalized people and gen-
erally receive less attention than other main stream
groups. Third, public health officials believe that interven-
tions towards this group are generally less effective and,
sometimes, less efficient than other groups because of
their tendencies to resist interventions and/or their lack of
freedom to choose healthy environments to live. Under
these conditions, not only do the inmates not receive
appropriate interventions they deserve, but the general
public also loses the benefits they may learn from studies
in the inmates. We therefore carried out a study in a prison
in central Thailand. We determined factors associated
with HIV seropositivity among the inmates, studied other
concomitant infections, verified if there were continued
uses of illegal drugs and continued homosexual practices
in the prison, and explored new HIV infections in the
prison.
Setting
The study was conducted in the Medical Correctional
Institution of the Klong Prem Central Prison, Bangkok,
Thailand. The prison is the largest one in Thailand and
served 7,177 inmates in 2002 [5]. The 300-bed hospital of
the prison treats approximately 250 inmates daily. Most
of them seek treatments for common respiratory tract
infections.
Methods
Participants and Follow-ups
Over the period of 15 months (between June 2001 and
August 2002), about 1,000 male inmates were
approached and invited to join the study. A total of 689
male inmates was eligible and agreed to be part of the
study. To be eligible for the study, the inmates must be
between 20–50 years old at the enrolment, have at least 5
years of remaining sentence term from the date of study,
not be seriously ill, and pass a test on basic knowledge
about HIV/AIDS. The test on basic HIV knowledge was
required as a part of participant's enrolment to ensure that
the study did not enroll those who are totally ignorant
about HIV and might not understand the significance of
their participation in the project. The staff of the project
explained the objectives and the nature of the study to the
potential participants. If they fitted the eligibility criteria
and agreed to join the study, a consent form was signed.
They were then interviewed about their demographics and
information related to their incarceration. There were no
potential participants who did not pass the basic test on
HIV knowledge. HIV risk behaviors before and during
incarceration were ascertained at the date of enrolment.
The risk behaviors were verified whether they were pre-
sented before the incarceration (Yes or No) and whether
they were continued or initiated during the incarceration
(Yes or No). The responses were then categorized into
"No/No" (never), "Yes/No" (before incarceration only),
"Yes/Yes" (continued into incarceration), and "No/Yes"
(initiated during incarceration).
Blood was taken for determination of HIV-1 and other
infectious profiles, complete blood count and blood
chemistry. Urine specimens were collected for determina-
tion of opiates and metamphetamine. Pre-test and post-
test counseling for anti-HIV testing was given to all
inmates by experienced nurses.
The follow-up period was 5 months. As a part of experi-
mentation of follow-up schedules, 500 inmates (72.6%)
were followed up only once at the end of 5 months. The
other 189 (27.4%) were followed up monthly for 5 times
during the study period. The rationale behind more fre-
quent visits in a part of the participants is to enable us to
detect early HIV seroconverters (if any) and to study these
early seroconverters in more details. However, financial
limitation of the project did not allow us to follow up all
participants on a monthly basis. For those who were fol-
lowed up on a monthly basis, they were interviewed,
counseled, physically examined, and blood tested at each
follow-up visit as they were at baseline. Risk behaviors
were assessed at the baseline and at the 5-month visit
only. In this study, the results of anti-HIV testing were
kept confidential and were not used to separate anti-HIV
positives from those who were negative. At the time of the
study, there were no programs that provide prophylaxis
for opportunistic infections or offer anti-retroviral for
HIV-infected prisoners.
There were no reported incidents of adverse consequences
associated with notifying HIV seropositives or serocon-
verters of their status. We also specifically asked, at the endBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/25
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of the study, if the participants experienced such adverse
consequences during their participation in the study and
none reported such experiences.
Data management and statistical analysis
All personal data of the inmates including their identifica-
tion, demographics, risk behaviors and laboratory find-
ings were kept confidential. Codes were used to identify
these subjects. All data were double entered by the inves-
tigators, using Microsoft Access version 97 (Microsoft Cor-
poration, New York, USA). Potential HIV risk factors were
examined using univariate and multivariate analyses. For
association of categorical variables, Yate's corrected chi
square test was used, except where the expected frequency
is less than 5 and Fisher's exact test is recommended. Var-
iables that were found statistically significant in the uni-
variate analysis and biologically plausible, as determined
by prior knowledge and suggested by literature, were
included in the multivariate analysis. Multiple logistic
regression analysis was used with anti-HIV status as the
outcome variable (Intercooled version 6, Stata Corpora-
tion College Station, Texas, USA). Maximum likelihood
ratio estimation was used to estimate the parameters and
the goodness of fit was applied to assess various models
during the model-fitting process. Likelihood ratio (LR)
test was applied to assess statistical significance. Both
crude odds ratio and adjusted odds ratios (ORs), with
associated 95% confidence intervals (CIs) and p-values,
were presented.
Drug use risks were assessed based on the inmates' injec-
tion history, history of attending drug abuse treatment
clinic, and urine test for opiates at the time of enrolment.
Injection history was further assessed based on duration
of injection, presence or absence of infection scar(s), and
history of sharing drug injection paraphernalia.
HIV seroconversion rate was also calculated among the
inmates who were HIV negative at enrolment and turned
HIV-positive during the follow-up period. Poisson estima-
tion was used to determine the rate and it's associated
95% confidence interval.
Laboratory tests
At the enrolment, the subjects were blood tested for Anti-
HIV antibody by HIV EIA (Uni-Form II plus O, Organon
Techinka, Boxtel, The Netherlands) with HIV-1 confirma-
tion by Western blot (HIV Blot 2.2, Gene Lab Diagnostic
Pte Ltd., Science Park, Singapore). The hepatitis B profiles
included HBsAg, HBc and HBs antibody EIA (ETI-MAK-4,
ETI-AB COREK-2 and ETI-AB-AUK-3, Diasorin s.r.1, Ver-
celli, Italy). The hepatitis C antibody was determined by
an EIA kit (ETI-AB-HCVK-3, Diasorin s.r.1, Vercelli, Italy).
The syphilis serology included VDRL, and TPHA (VDRL,
Syphscreen RPR, Porton Cambridge, Kennett, United
Kingdom and Syphilis TPHA tests, Human, Wies baden,
Germany). In addition, anti HSV-2 IgM EIA (Capita HSV-
2 IgM, Trinity Biotech, New York, USA) and anti-chlamy-
dia IgM EIA (Sero ELISA chlamydia true IgM, Savyon
Diagnostics Ltd., Ashdod, Israel) were also carried out.
Table 1: Demographic characteristics and laboratory test results 
of 689 male inmates at the enrolment, Bangkok Thailand, 2001–
2002.
Characteristics Number (%)*
Age (years)
Mean ± SD 32.3 ± 6.7
Median (Range) 32(20–50)
Marital status
Single 293 (42.6)
Married 237 (34.5)
Divorced, separated and widowed 157 (22.9)
Home town
Bangkok and its suburbs 334 (48.5)
Other locations in Thailand 310 (45.0)
Outside Thailand (foreigners) 45 (6.5)
Highest education level
Primary 354 (52.3)
Secondary or Higher 323 (47.7)
Occupation before incarceration
No occupation 44 (6.4)
Labor 463 (67.2)
Private business 116 (16.8)
Others 66 (9.6)
Monthly income (Baht) excluding the 
unemployed**
Mean ± SD 12,788 ± 25,157
Median(Range) 6,000 (330–250,000)
Type of offense
Narcotic-related 298 (45.9)
Life- or sex-offended 179 (27.6)
Theft or robbery 172 (26.5)
Term of sentence (years)
Mean ± SD 18.9 ± 8.4
Median (Range) 18(5.7–30.0)
Duration of sentence already served (years)
Mean ± SD 5.8 ± 3.9
Median(Range) 5.0(1.0–18.0)
Laboratory profiles (% positivity)
Anti HIV antibody 175 (25.4)
Anti HCV antibody 309 (44.9)
HBs Antigen 77 (11.2)
Anti HBc antibody 442 (64.2)
Anti HBs antibody 286 (41.5)
Anti Chlamydia IgM antibody 140 (20.3)
VDRL with TPHA confirmation 22 (3.2)
Anti HSV2 IgM antibody 72 (10.4)
Urine opiates 78 (11.3)
Urine metamphetamines 42 (6.1)
Note: *The total numbers may not add up to 689 because of no 
responses from some participants. **1 US dollar = 43 Baht 
(approximately)BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/25
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Urine was tested for opiates and metamphetamine (Cap-
ita EIA test kit, Trinity Biotech, New York, USA). Complete
blood count was analyzed by an automated analyzer
(Counter-HmX, Florida, USA). Blood chemistry profiles
included liver function test, lipid and renal profiles and
were tested by an automated analyzer (Cobas Mira, Roche
Boehringer Mannheim, Mannheim Germany). All labora-
tory tests were performed only at the enrolment, except
for HIV and HCV serology that were tested at every visit.
Ethical Review
The Ethical Review Committee for Research in Human
Subjects of the Ministry of Public Health of Thailand
approved the study protocol in March 2001.
Results
Demographic characteristics, risk behaviors and 
laboratory results
During the study period, there were 689 male inmates
who were eligible and agreed to join the study. Most of
them are young with the median age of 32 years. Nearly
half are single and are residents of Bangkok and its sub-
urbs. Only half have highest education at primary level.
Before incarceration, 62.7% of the inmates were labor
workers with the median monthly income of 6,000 Thai
Baht (about 136 USD). About 43% were incarcerated for
narcotic-related offenses, with the median sentence term
of 18 years. About 62.4% of the inmates had been incar-
cerated for 5 years or more. Details of their demographic
data are illustrated in table 1.
HIV risk behaviors before and during incarceration
Potential HIV risk behaviors of the inmates are described
in table 2. Among the 689 inmates, 351 (50.9%) reported
drug injection before or during incarceration or both. Out
of the 351 injectors, 83 (15.6%) injected drug before
incarceration only, 80 (15.9%) initiated injection while
incarcerated and 188 (53.6%) continued drug injection
into the incarceration. Nearly all (333 or 94.9%) injectors
had an experience of sharing injection paraphernalia with
other injectors. Among the 333 inmates who shared injec-
tion, 74 (22.2%) shared equipment before incarceration
only, 92 (27.6%) initiated sharing equipment during
incarceration and 167 (50.2%) continued sharing behav-
iors while incarcerated. Nearly half (161 or 45.9%) of the
351 injectors had injection scars on their bodies and 78
(22.2%) of the injectors had positive urine opiate test. Tat-
tooing and sharing razor blade were also common risk
behaviors in the inmates. Receiving blood transfusion was
not very frequent (7.8%) among the inmates.
Sexual risks of the 689 male inmates before incarceration
were mainly heterosexual ones. Most of them (81.4%) vis-
ited prostitutes at least once. About 80% reported having
sex with non-wife women. More than 95% reported expe-
riences of unprotected sex. More than one quarter of the
inmates reported sex with men. Among those who had sex
with men, more than 80% continued into the incarcera-
tion or initiated during the incarceration. Since condom is
practically unavailable in the prison, most of this kind of
sex is likely to be unprotected.
Table 2: HIV risk factors before and during incarceration of 689 male inmates, Bangkok Thailand, 2001 – 2002.
Risk factors Risk before and during incarceration, Number (%)
No/No Yes/No No/Yes Yes/Yes p-values
Heroin injection 338(49.1) 83(12.0) 80(11.6) 188 (27.3) <0.001
Injection risk among 351 heroin injectors
- Sharing injection paraphernalia 18 (5.1) 74(21.1) 92(26.2) 167 (47.6) 0.007
- Presence of injection scar(s) on the body* 190 (54.1) 161(45.9)
- Positive urine opiates* 273 (77.8) 78(22.2)
- Having attended withdrawal clinics* 240 (63.4) 111(36.6)
- Injection duration >7 years* 205 (58.4) 144(41.0)
Presence of tattoos 228 (33.1) 127 (18.4) 168 (24.4) 166(24.1) 0.003
Sharing razor blades with others 150 (21.8) 31 (4.5) 211 (30.6) 297(43.1) <0.001
Ever receiving blood transfusion 635 (92.2) 51 (7.4) 1 (0.2) 2(0.3) 0.017**
Ever visiting prostitute* 128 (18.6) 561 (81.4)
Having sex with non-wife women* 144 (20.9) 545 (79.1)
Having sex without condom 21(3.8) 531(79.1) 7(1.0) 130(18.9) 0.652
Having sex with men 507(73.6) 40 (5.8) 78(11.3) 64 (9.3) <0.001
Having sexually transmitted diseases 393 (57.0) 288(41.8) 1 (0.2) 7 (1.0) 0.024**
Note: No/No = Never, Yes/Yes = Continued into incarceration, Yes/No = Before incarceration only, No/Yes = Initiated during incarceration 
*These risk behaviors were ascertained at the time of enrolment. **Fisher's exact testBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/25
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Table 3: Univariate analysis of HIV risk factors among 689 male inmates, Bangkok Thailand, 2001–2002.
Factors Anti-HIV positivity N (%) Unadjusted OR 95 % CI p-value
Demographics
Age (years, median)
≤ 32 93/378 (24.6) 1.00
>32 82/311 (26.4) 1.10 0.78–1.55 0.60
Marital status
Single 74/293 (25.3) 1.00
Ever married 101/396 (25.5) 1.01 0.72–1.43 0.94
Home town
Bangkok/suburbs 81/334 (24.3) 1.00
Other places 94/355 (26.5) 1.12 0.80–1.56 0.50
Highest education level
Primary 89/347 (25.7) 1.00
Secondary or higher 79/323 (24.5) 0.94 0.66–1.33 0.72
Employment
Unemployed 13/44 (29.6) 1.00
Employed 162/645 (25.1) 0.80 0.41–1.55 0.51
Monthly income excluding the unemployed 
(Baht, median)
≤ 6000 72/326 (22.1) 1.00
> 6000 81/297 (27.3) 1.32 0.92–1.91 0.13
Type of offense
Narcotic-related 82/298 (27.5) 1.00
Others 93/391 (23.8) 0.82 0.58–1.16 0.26
Term of sentence (years, median)
≤ 18 45/150 (30.0) 1.00
> 18 44/148 (29.7) 1.00 0.60–1.62 0.96
Duration of sentence already served (years, 
median)
≤ 5 59/185 (31.9) 1.00
>5 30/111 (27.0) 0.79 0.47–1.33 0.78
Blood-related risk
History of heroin injection
- Never 13/338 (3.9) 1.00
- Before incarceration only 20/83 (24.1) 7.94 3.80–16.58 <0.001
- Continued into incarceration 99/188 (52.7) 27.81 15.00–51.48 <0.001
- Initiated during incarceration 43/80 (53.8) 29.05 14.42–58.49 <0.001
Urine opiate test
Non-reactive 117/611 (19.2) 1.00
Reactive 58/78 (74.4) 12.24 7.12–21.05 <0.001
Ever attending withdrawal clinic
Never 109/578 (18.9) 1.00
Ever 66/111 (59.5) 6.31 4.10–9.71 <0.001
Tattooing
- Never 17/228 (7.5) 1.00
- Before incarceration only 34/127 (26.8) 4.54 2.43–8.47 <0.001
- Continued into incarceration 62/166 (37.4) 7.40 4.14–13.21 <0.001
- Initiated during incarceration 62/168 (36.9) 7.26 4.06–13.00 <0.001
Sharing razor blades
Never 27/150 (18.0) Referent
Ever 139/538 (25.8) 1.72 1.09–2.72 0.019
Receiving blood transfusion
Never 162/635 (25.5) Referent
Ever 13/54 (24.1) 0.93 0.49–1.76 0.816
Risk factors among 351 injectors only
Sharing injection paraphernalia
No 5/19 (26.32) Referent
Yes 157/332 (47.29) 2.51 0.92–6.85 0.074
Injection scars
No 59/190 (31.05) Referent
Yes 103/161 (63.98) 3.94 2.53–6.15 <0.001BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/25
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HIV-1 positivity and risk factors
The overall anti-HIV positivity was 175/689 or 25.4%
(95%CI: 22.0 – 28.6%). In the univariate analysis as
shown in table 3, demographic characteristics, incarcera-
tion-related factors, and most sexual risk behaviors
(except for unprotected sex) were not statistically associ-
ated with HIV positivity.
Strong association with HIV positivity was observed in the
inmates who engaged in drugs injection, had reactive
urine opiate test, attended withdrawal clinics, had tattoos
and shared razor blade and had unprotected sex (p<
0.05). Higher HIV positivity was observed more among
the inmates who initiated or continued such risks during
the incarceration than those who declared no such risks at
all or had risks only before incarceration.
Among the 351 injectors, HIV positivity was associated
with history of sharing injection equipment, presence of
injection scar(s), and injection duration more than 7
years.
After being adjusted for age in the multiple logistic regres-
sion analysis, variables found to remain statistically signif-
icant are injection history, history of attending drug
withdrawal clinic, urine opiates, and body tattoos. The
adjusted odds ratios and associated confidence intervals
are shown in table 4.
HIV seroconversion rate
Out of the 689 inmates, 166 (25.4%) were anti-HIV posi-
tive at the enrolment. The remaining 523 inmates were
followed-up for a period of 5 months. Successful follow-
up rate was 98.7%. During the follow up period (2,581
person-months), 9 inmates got HIV seroconversion, cor-
responding to the estimated HIV-1 incidence of 4.18 per
100 person-years (95% CI: 4.11 – 4.26 per 100 person-
years). All 9 HIV incident cases were injectors. When we
restricted the calculation only to the injectors, the HIV-1
incidence would be 11.10 per 100 person-years (95% CI:
Injection duration (years, median)
≤ 7 73/207 (35.27) Referent
>7 89/144 (61.81) 2.97 1.91–4.61 <0.001
Sexual risks
Visiting prostitute before incarceration
Never 39/128 (30.5) Referent
Ever 136/561 (24.2) 0.73 0.48–1.11 0.144
Sex with non-wife women
Never 44/143 (30.8) Referent
Ever 131/546 (24.0) 0.71 0.47–1.06 0.098
Unprotected sex (sex without condom)
Never 14/20 (70.0) Referent
Ever 161/669 (24.1) 0.14 0.05–0.35 <0.001
Sex with men
- Never 123/506 (24.3) Referent
- Before incarceration only 13/40 (32.5) 1.50 0.76–2.97 0.249
- Continued into incarceration 20/64 (31.2) 1.42 0.81–2.48 0.228
- Initiated during incarceration 19/79 (24.0) 0.99 0.57–1.71 0.960
Having sexually transmitted diseases
Never 102/393 (26.0) Referent
Ever 73/296 (24.7) 0.93 0.66–1.32 0.700
Table 3: Univariate analysis of HIV risk factors among 689 male inmates, Bangkok Thailand, 2001–2002. (Continued)
Table 4: Multiple logistic regression analysis of HIV risk factors 
among 689 male inmates, Bangkok Thailand, 2001–2002.
Factors Adjusted OR 95% CI p-values
Age 0.99 0.96–1.02 0.480
Injection history*
No 1.00
Yes 2.30 1.91–2.77 <0.001
History of attending 
withdrawal
Clinic
No 1.00
Yes 2.00 1.19–3.35 0.009
Positive urine opiate test
No 1.00
Yes 5.04 2.63–9.67 <0.001
Presence of tattoos on 
the body
No 1.00
Yes 1.23 1.01–1.52 0.048
* Injection history included information of injection before or after 
incarceration, presence or absence of injection scars, history of 
sharing injection paraphernalia and injection duration.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/25
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10.89–11.31 per 100 person-years) during 973 person-
months of observation.
Other infectious markers and drug uses
The seroprevalence of certain infectious diseases and
drugs are shown in table 1. Among the 689 inmates, high
prevalence of hepatitis viral infections was observed as
follows: 309 (44.85%) for anti HCV, 77 (11.18%) for
HBV s antigen, 286 (41.51%) for anti HBs, and 442
(64.15%) for anti HBc. There were 140 inmates (20.32%)
who were reactive for Chlamydia IgM.
Other sexually transmitted diseases than HIV-1 were also
studied, e.g, 72 (10.45%) reactive for HSV-2 IgM and only
22 (3.19%) reactive for Syphilis with TPHA confirmation.
In addition, continued use of illegal drugs inside the
prison was observed, e.g. 78 (11.82%) for opiates and 42
(6.1%) for metamphetamine as determined by urine
testing.
Discussion and conclusion
HIV-1 prevalence of these Bangkok inmates was 25.4%
which is quite high but comparable to that of 20% in the
US and South African prisons but higher than that of
13.7% in Brazilian prisons [2,6,3]. HIV prevalence of the
inmates with drug injection and sharing injection equip-
ment while incarcerated was reported to be as high as 53–
57% in several studies including the rate of 53.4% in cen-
tral Thailand that was reported in HIV-1 sentinel surveil-
lance in the year 2000 [1].
The overall HIV-1 seroconversion rate of the inmates in
this study is 4.18 per 100 person years, which is compara-
ble to that of Bangkok injection drug user [7]. However,
HIV-1 incidence rate of 11.10 per 100 person years among
the inmates with injection risk was observed. This is about
one-third of the rate of 35 per 100 person-years in Bang-
kok injection drug users who continued drug injection
while incarcerated [8] and 31.3 per 100 per person-years
among injection drug users in the north Thailand [9].
Such substantially lower HIV-1 incidence rates in this
study are probably due to scarcity of the abuse drugs and
injection equipment, differences in sentence term, prohi-
bition of all kinds of sexual behaviors inside the prison
and limitation on follow-up time and number of partici-
pants. More studies may be needed to clarify these issues.
Despite the limitations imposed on the inmates, some of
them continued risk behaviors into the incarceration or
initiated such behaviors during the incarceration. Such
practices remain them at the high risk for HIV and other
infections.
In this study, high burdens of infections other than HIV-1
among the inmates were also observed, e.g. HCV and HBV
infections. Such high risk of hepatitis viral infections were
consistent with previous reports in Brazilian prisons (41%
for HCV and 68.1% for HBV) and in Spanish prisons
(42.5% for HCV and HBV co-infections), but the rates
were considerably lower than those in Danish prisons
(64% for HCV and 87% for HBV) and among Austrian
imprisoned injection drug users (75% for HCV and 68%
for HBV) [3,10–12].
Inmates are still at high risk for HIV and need more atten-
tion. Firstly, inmates are still at risk of sex transmission of
HIV despite their physical containment. As a matter of
fact, high heterosexual risks and sexual transmitted dis-
eases among injection drug users are recently reported in
Vancouver injection drug users [14]. Secondly, inmates
will be part of the outside society once they finish their
term in prison. Understanding their risks of HIV and
injection drug use and providing proper interventions
offer benefits not only to the inmates, their families and
their partners, but also to the public health of the commu-
nities to which they will return. Finally, these inmates are
neglected people. Drug treatment and HIV intervention
programs for the inmates received only 5,910,000 Thai
Baht (about 137,405 USD) for 247,415 inmates for the
whole country [15]. With the estimated number of about
60,000 HIV-positive inmates and almost 100,000 inmates
who continue use of drug during incarceration, this
amount of budget is certainly fall short of need.
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